Anne Chiang, MD

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

In a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

Anne Chiang, MD, PhD, discusses treatment options for patients with extensive-stage small cell lung cancer.

Anne Chiang, MD, PhD, discusses the management of ​immune-related adverse effects in lung cancer. 

A new FDA program is giving patients and providers first-time access to patient-reported outcome data from cancer clinical trials of marketed treatments.

Consolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.